2017
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Research And Treatment 2017, 164: 107-117. PMID: 28364214, PMCID: PMC5479131, DOI: 10.1007/s10549-017-4222-8.Peer-Reviewed Original ResearchConceptsOlder breast cancer patientsLong-term mortalityBreast cancer patientsCancer patientsHormonal therapyRobust patientsFrailty indexBreast cancer-specific mortalityDeficit-accumulation frailty indexAbsolute mortality differencePurposeBreast cancer patientsAdjusted hazard ratioCancer-specific mortalityBreast cancer deathsInvasive breast cancerBreast cancer mortalityAdjusted hazardFrailty categoriesCause mortalityFrail patientsMore chemotherapyFrailty statusHazard ratioOlder patientsClinical factors
2016
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research And Treatment 2016, 157: 587-596. PMID: 27271765, DOI: 10.1007/s10549-016-3845-5.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerMedian overall survivalOverall survivalPopulation-based analysisDuctal carcinomaLobular carcinomaAnnual percent changeBreast cancerIncidence rateDe novo metastatic breast cancerEnd Results 9 registriesHormone receptor-positive tumorsNovo metastatic breast cancerMultivariable Cox regression modelsStage IV breast cancerAnnual age-adjusted incidence ratesAge-adjusted incidence ratesAdjusted hazard ratioBetter overall survivalDate of diagnosisReceptor-positive tumorsBreast cancer incidenceCox regression modelHazard ratioTumor histology
2014
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Research And Treatment 2014, 145: 491-501. PMID: 24756187, DOI: 10.1007/s10549-014-2968-9.Peer-Reviewed Original ResearchConceptsNon-standard chemotherapyTrastuzumab-based therapyAdjuvant trastuzumab-based therapyOlder womenChemotherapy receiptHazard ratioBreast cancerHER2-positive breast cancerPattern of chemotherapyPropensity-weighted cohortsToxicity-related hospitalizationAdjusted hazard ratioTreatment-related toxicityMonths of chemotherapyShort-term outcomesMultivariable logistic regressionPopulation-based cohortPropensity score adjustmentAssociation of ageShort-term survivalComorbidity scoreOlder patientsTreatment toxicityWorse survivalHospital events
2012
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. Journal Of Clinical Oncology 2012, 30: 4071-4076. PMID: 22826271, PMCID: PMC3494835, DOI: 10.1200/jco.2011.40.6405.Peer-Reviewed Original ResearchConceptsRelapse-free survivalHuman epidermal growth factor receptor 2Primary breast cancerPositive nodesBreast cancerHazard ratioAdjuvant chemotherapyChemotherapy regimenEstrogen receptor/progesterone receptorPrimary efficacy end pointEpidermal growth factor receptor 2Dose-dense fashionDoxorubicin/cyclophosphamideAdjusted hazard ratioCycles of doxorubicinEfficacy end pointOperable breast cancerPositive axillary nodesER/PgRGrowth factor receptor 2Factor receptor 2Chemotherapy regimensAxillary nodesMenopausal statusClinical outcomes